Target Audience. This enduring material is designed for psychiatrists, neurologists and other physicians who prescribe or manage the side effects of antipsychotic medications.

Needs Assessment. Drs. Friedman and Weiden are frequently asked to consult on movement disorders in patients receiving antipsychotic medications, and it is their experience that prescribing physicians often underrecognize these disorders and may consider EPS to be a problem of the past now that many patients are treated with "atypical" antipsychotic medications.

Accreditation Statement. Brown Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the Essential Areas and policies of the ACCME.

Credit Statement. Brown Medical School designates this educational activity for 3 hours in Category 1 credit toward the AMA Physician's Recognition Award.

Date of Original Release. EPS: A Guide to Prevention, Recognition and Treatment in the Era of Atypical Antipsychotics was published in December 2000. This activity is eligible for CME credit through November 2002.

To Obtain Credit: Please request a copy of the program kit via the Enroll link on this website. You will receive a kit which will include a post-test. The test should be returned to John Armstrong & Co., Inc., and respondents must receive a score of 70 or higher for credit. Processing of CME credit has been funded by a grant from AstraZeneca Pharmaceuticals LP.

Faculty Disclosure. In accordance with the disclosure policy of Brown Medical School as well as standards set forth by the Accreditation Council on Continuing Medical Education (ACCME), faculty members have been asked to disclose (1) any significant financial or any other relationships with the manufacturers or any commercial producers and/or providers of commercial services discussed in any educational presentation and (2) with any commercial supporters of this activity.

The intent of this policy is not to prevent an author with a potential conflict of interest from making a presentation. It is merely intended that any potential conflict should be identified openly so that the participant may form his/her own opinion.

Joseph H. Friedman, MD is a consultant to AstraZeneca, Bristol Meyers Squibb, Merck KGa and Novartis. He is a member of speaker's bureaus for AstraZeneca, Novartis, Pharmacia and Roche. Peter J. Weiden, MD consults for AstraZeneca, Janssen Pharmaceutica, Lilly and Pfizer; he has received grant research support from AstraZeneca, Lilly and Pfizer; and he speaks for AstraZeneca, Janssen, Lilly and Pfizer.

Acknowledgement. This activity was developed by John Armstrong & Company, Inc. The opinions expressed herein are those of the authors and do not necessarily reflect the views of the sponsor or the commercial supporter.